ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Browse : By Sponsor : National Institutes of Health : ALL_STUDIES


Include trials that are no longer recruiting patients.

8117 studies were found. Here are studies 1 to 50.
1.No longer recruiting"Clinical Trials to Enhance Elders' Oral Health" ("TEETH")
Conditions: Tooth Loss; Periodontal Disease; Tooth decay
2.CompletedA "Pre-Enrollment" Protocol for HIV-Infected Adolescents
Condition: HIV Infections
3.RecruitingThe "Reach For Health" Program: Delaying Sexual Activity in Children
Conditions: Sex Behavior; Child Behavior
4.No longer recruiting(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients who Receive Neurotoxic Therapy
Conditions: Cancer; Central Nervous System Disease; Nervous System Disease; Peripheral Nervous System Disease; Progressive Multifocal Leukoencephalopathy
5.Completed(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC
Condition: HIV Infections
6.Completed1-Octanol to Treat Essential Tremor
Condition: Essential Tremor
7.Completed1-Octanol to Treat Essential Tremor
Condition: Essential Tremor
8.Suspended10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma
9.No longer recruiting10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Conditions: stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; recurrent non-small cell lung cancer; Quality of Life
10.Completed10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific
11.Recruiting12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm
12.Recruiting131MIBG to Treat Malignant Pheochromocytoma
Condition: Pheochromocytoma
13.Recruiting17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer
14.Recruiting17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: Cancer
15.Recruiting17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma
16.Recruiting17-DMAG to Treat Patients with Solid Tumors or Lymphomas
Conditions: Neoplasms; Lymphoma
17.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Condition: unspecified adult solid tumor, protocol specific
18.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Condition: Cancer
19.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma
20.Not yet recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer
21.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Conditions: adult Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; adult non-Hodgkin's lymphoma; adult solid tumor; Cutaneous T-Cell Lymphoma; ...
22.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Stage III or Stage IV Melanoma
Conditions: stage III melanoma; Stage IV Melanoma; Recurrent Melanoma
23.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
Conditions: stage I renal cell cancer; von Hippel-Lindau Syndrome
24.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Conditions: Ewing's family of tumors; childhood rhabdomyosarcoma; childhood soft tissue sarcoma; hematopoietic and lymphoid cancer; Neuroblastoma; Osteosarcoma
25.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: unspecified childhood solid tumor, protocol specific; recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia; ...
26.Recruiting17AAG to Treat Kidney Tumors in von Hippel-Lindau Disease
Conditions: Hippel-Lindau Disease; Kidney Cancer
27.No longer recruiting2-Methoxyestradiol (2-ME2) to Treat Solid Tumor Cancers
Conditions: Pathologic Angiogenesis; Neoplasm
28.Recruiting2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific
29.Not yet recruiting3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer
30.Recruiting3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
Condition: unspecified adult solid tumor, protocol specific
31.Recruiting3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
Conditions: recurrent non-small cell lung cancer; stage IV non-small cell lung cancer
32.Recruiting3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
Condition: Non-small cell lung cancer
33.Recruiting3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ...
34.Recruiting3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer
Conditions: unresectable extrahepatic bile duct cancer; recurrent gallbladder cancer; unresectable gallbladder cancer; recurrent extrahepatic bile duct cancer; ...
35.Recruiting3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Chronic Myelogenous Leukemia; secondary acute myeloid leukemia
36.Recruiting3-AP as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma (Cancer) of the Pancreas
Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ...
37.Recruiting3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: acute leukemia; adult acute monoblastic and acute monocytic leukemia; atypical chronic myeloid leukemia; chronic leukemia; ...
38.Recruiting3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
Conditions: recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
39.Recruiting3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Conditions: recurrent esophageal cancer; stage IV esophageal cancer; Adenocarcinoma of the Esophagus
40.Recruiting3-D Laser Imaging to Analyze Neck Movement
Conditions: Neck Pain; Manipulation, Spinal
41.Recruiting3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection
Conditions: stage I breast cancer; stage II breast cancer
42.No longer recruiting4'-Iodo-4'-deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: primary systemic amyloidosis
43.Recruiting4-Day-A-Week Treatment Plan for HIV Infected Adolescents
Condition: HIV Infections
44.No longer recruiting41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
Condition: Rheumatic Diseases
45.CompletedA 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
Condition: Multiple Sclerosis
46.Completed5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
Condition: Beta Thalassemia
47.Completed506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
Conditions: refractory chronic lymphocytic leukemia; T-cell chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
48.No longer recruiting506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Conditions: Leukemia; Lymphoma; Multiple Myeloma
49.No longer recruiting506U78 in Treating Patients With Lymphoma
Conditions: Leukemia; Lymphoma
50.Suspended506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
Conditions: recurrent adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; L2 adult acute lymphoblastic leukemia; ...

line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act